A Real-World Observational Analysis Comparing the Effectiveness and Safety of Treatment with Apixaban Versus Other Oral Anticoagulants Among Elderly Non-valvular Atrial Fibrillation Patients.

Trial Profile

A Real-World Observational Analysis Comparing the Effectiveness and Safety of Treatment with Apixaban Versus Other Oral Anticoagulants Among Elderly Non-valvular Atrial Fibrillation Patients.

Completed
Phase of Trial: Phase IV

Latest Information Update: 06 Sep 2017

At a glance

  • Drugs Apixaban (Primary) ; Dabigatran etexilate; Rivaroxaban; Warfarin
  • Indications Embolism; Stroke
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 06 Sep 2017 New trial record
    • 30 Aug 2017 Results presented at the ESC Congress 2017: Annual Congress of the European Society of Cardiology
    • 29 Aug 2017 According to a Bristol-Myers Squibb Media Release, findings from this study supplement results from the landmark phase 3 ARISTOTLE trial.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top